Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00505245 · ClinicalTrials.gov registry record
New Assessment System in Measuring Symptom Distress in Cancer Patients
A clinical trial of Malignant Neoplasm and Caregiver, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- 6,500
- Enrollment target
- 1
- Study location
NCT00505245 is a study of Malignant Neoplasm and Caregiver that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 6,500 participants, above the 403-participant average among 59 other Malignant Neoplasm trials with a reported enrollment target (1513% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00505245, a study of Malignant Neoplasm and Caregiver, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- 6,500 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial studies how well a new assessment system (MDASI or other MD Anderson-developed PRO instrument) works in measuring symptoms and the impact on quality of life in cancer patients. Development of a new assessment system may provide more information about the common symptoms that may occur in patients due to cancer and its treatment and how the symptoms impact quality of life.
Conditions Studied
Interventions
- OTHER Quality-of-Life Assessment
- OTHER Questionnaire Administration
- OTHER Interview
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6,500 participants |
| Start Date | 1999-04-13 |
| Est. Completion | 2031-04-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00505245
The ClinicalTrials.gov registry entry for NCT00505245 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 6,500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 403-participant average among 59 other Malignant Neoplasm trials with a reported enrollment target (1513% higher). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Malignant Neoplasm appearing as the primary indexed condition, and to 3 interventions - of which Quality-of-Life Assessment is the first listed.
NCT00505245 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00505245 about?
NCT00505245 is a clinical study titled "New Assessment System in Measuring Symptom Distress in Cancer Patients". This trial studies how well a new assessment system (MDASI or other MD Anderson-developed PRO instrument) works in measuring symptoms and the impact on quality of life in cancer patients. Development of a new assessment system may provide more information about the common symptoms that may occur in ...
What is the current status of trial NCT00505245?
This trial is currently recruiting. The enrollment target is 6,500 participants. The study started on 1999-04-13. Estimated completion is 2031-04-30.
What conditions does trial NCT00505245 study?
This clinical trial studies the following conditions: Malignant Neoplasm, Caregiver, Health Care Provider, Physician.
What interventions are being tested in trial NCT00505245?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Questionnaire Administration (OTHER), Interview (OTHER).
Who is sponsoring clinical trial NCT00505245?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00505245 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
RECRUITING · Phase 1
-
Pre-operative SRS or Post-operative SRS in Treating Cancer Patients With Brain Metastases
RECRUITING · Phase 3
-
Germ-Line Mutations in Blood and Saliva Samples From Patients With Cancer
RECRUITING
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
Engagement of American Indians of Southwestern Tribal Nations in Cancer Genome Sequencing
RECRUITING · NA
-
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.